Celcuity Expects $441.5M Cash at End of FY2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy CELC?
Cash, cash equivalents and short-term investments were $441.5M at the end of fiscal year 2025 and are expected to finance our operations through 2027. "We expect this year to be a transformative one for Celcuity. We plan to release topline results from the PIK3CA mutant cohort of our Phase 3 VIKTORIA-1 study in the second quarter of 2026, which, if positive, could potentially advance the standard-of-care second line therapy for a significant number of patients with HR+/HER2- advanced breast cancer," said Brian Sullivan, CEO and co-founder of Celcuity. "Additionally, our efforts remain on track to launch gedatolisib commercially in anticipation of its potential FDA approval in the third quarter of 2026."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CELC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CELC
Wall Street analysts forecast CELC stock price to fall
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 108.270
Low
94.00
Averages
106.50
High
126.00
Current: 108.270
Low
94.00
Averages
106.50
High
126.00
About CELC
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Celcuity Reports Final 2025 Financial Results with Narrower Loss
- Financial Performance Surprise: Celcuity reported a net loss of $38.4 million ($0.73 per share) for Q4 2025, which, while deeper than the $32.3 million loss in 2024, was significantly better than analysts' expectations of a $1.05 loss per share, indicating effective cost management.
- Increased R&D Spending: The company did not report any revenue but saw operating expenses rise to over $49 million in Q4, up from over $36 million in the same period of 2024, reflecting its ongoing commitment to research and development during this phase.
- Strong Cash Reserves: Celcuity's cash and cash equivalents totaled nearly $166 million at the end of the quarter, a substantial increase from $22.5 million at the end of 2024, providing a solid financial foundation to support its operations without revenue.
- Optimistic Clinical Trial Outlook: The company anticipates topline results from its phase 3 clinical trial of gedatolisib for advanced breast cancer in Q2, which, if positive, could significantly boost market confidence in its growth potential.
See More
Celcuity Reports Final 2025 Financial Results with Surprising Bottom-Line Upside
- Financial Performance Surprises: Celcuity reported a net loss of $38.4 million ($0.73 per share) for Q4 2025, which, while deeper than last year's $32.3 million, was significantly better than analysts' expectations of a $1.05 loss per share, indicating effective cost management.
- Strong Cash Position: The company's cash and cash equivalents rose to nearly $166 million at the end of Q4 2025, up from $22.5 million at the end of 2024, providing a solid financial runway for its ongoing research and development efforts, which is crucial for pre-revenue biotechs.
- Promising R&D Developments: Celcuity anticipates topline results from a phase 3 clinical trial of gedatolisib for advanced breast cancer in Q2, which, regardless of the outcome, could lay the groundwork for future revenue opportunities.
- Positive Market Reaction: Following the earnings release, Celcuity's stock surged over 4%, reflecting investor optimism about the company's future potential, particularly given its robust cash foundation.
See More
Meta Platforms Faces Legal Setbacks, Stock Drops Over 6%
- Meta Legal Setbacks: Meta Platforms' stock dropped over 6% following losses in two major legal cases concerning child safety, raising concerns about Big Tech's role in social media safety and free speech protections, despite relatively minor financial penalties.
- AppLovin's Decline: AppLovin's shares fell nearly 8% due to reports of weakening e-commerce spending trends, with insufficient new client momentum to offset churn in Q1, highlighting potential challenges in maintaining growth.
- Brown-Forman's Surge: Shares of Brown-Forman rose over 14% after Bloomberg reported that French spirits company Pernod Ricard is considering a bid, indicating strong market interest in the company's future acquisition potential.
- Pony AI's Expansion Plans: Pony AI's stock fell 13% after announcing ambitious robotaxi expansion plans alongside its first quarterly profit, but an 18% revenue drop due to project timing raises concerns about margin pressures despite doubling robotaxi revenue.
See More
Memory Stocks Plummet, Adobe Downgraded
- Memory Stock Decline: Shares of memory chipmakers fell sharply following Google's unveiling of a new AI model, with Sandisk dropping nearly 4% and Micron Technology, Western Digital, and Seagate Technology each declining about 2%, indicating significant memory demand pressures in the industry.
- Mining Stocks Drop: Shares of gold and silver miners fell alongside declining precious metal prices, with First Majestic Silver shedding about 5% and both Coeur Mining and Hecla Mining losing nearly 4%, reflecting a bearish sentiment in the precious metals market.
- Adobe Downgrade: Adobe's stock dipped 1.4% after William Blair downgraded it from outperform to market perform, highlighting uncertainty regarding its position as an AI winner or loser, which may impact investor confidence.
- Navan's Strong Guidance: Travel tech firm Navan soared 18% after guiding for strong revenue in 2027, expecting full-year revenue between $866 million and $874 million, exceeding market expectations, showcasing its robust growth potential in the industry.
See More
Celcuity Reports 2025 Financial Results and FDA Progress
- FDA Priority Review: Celcuity's NDA for Gedatolisib in HR+/HER2/PIK3CA wild-type advanced breast cancer has been accepted by the FDA with a Priority Review designation, setting a PDUFA goal date of July 17, 2026, which could pave the way for future commercialization.
- Increased Financial Loss: In Q4 2025, Celcuity reported a net loss of $51 million, or $0.97 per share, compared to a net loss of $36.7 million, or $0.85 per share in Q4 2024, reflecting the company's ongoing investment in research and development.
- Clinical Trial Advancements: The VIKTORIA-1 Phase 3 trial's PIK3CA wild-type cohort has completed enrollment, with updated efficacy and safety results published in the Journal of Clinical Oncology, while topline data from the PIK3CA-mutant cohort is expected in Q2 2026, potentially influencing future treatment protocols.
- Strong Cash Position: Celcuity ended the year with $441.5 million in cash and short-term investments, which is expected to fund operations through 2027, demonstrating financial resilience in its R&D and market launch efforts.
See More
Celcuity Reports $177 Million Net Loss for 2025 Amid Regulatory Progress
- Poor Financial Performance: Celcuity reported a net loss of $177 million for 2025, translating to a loss of $3.79 per share, indicating significant challenges in profitability despite holding $441.5 million in cash and short-term investments, which is expected to sustain operations through 2027.
- Increased R&D Expenses: Research and development expenses surged to $145 million in 2025, an increase of $40.8 million from the previous year, primarily driven by rising employee and consulting costs, which will exert ongoing pressure on the company's financial health and future investment capabilities.
- Significant Clinical Progress: In 2025, Celcuity achieved FDA acceptance of its new drug application for gedatolisib with priority review, and the VICTORIA-1 trial demonstrated unprecedented efficacy data, potentially setting new benchmarks for HR-positive HER2-negative advanced breast cancer treatment, thereby enhancing market competitiveness.
- Market Readiness Initiatives: The company has made substantial strides in preparing for the commercial launch of gedatolisib, including building a robust sales force and engaging with key healthcare decision-makers, which will help secure a favorable position in the future market, despite challenges in ensuring patient adherence to IV administration.
See More
Celcuity Reports Final 2025 Financial Results with Narrower Loss
- Financial Performance Surprise: Celcuity reported a net loss of $38.4 million ($0.73 per share) for Q4 2025, which, while deeper than the $32.3 million loss in 2024, was significantly better than analysts' expectations of a $1.05 loss per share, indicating effective cost management.
- Increased R&D Spending: The company did not report any revenue but saw operating expenses rise to over $49 million in Q4, up from over $36 million in the same period of 2024, reflecting its ongoing commitment to research and development during this phase.
- Strong Cash Reserves: Celcuity's cash and cash equivalents totaled nearly $166 million at the end of the quarter, a substantial increase from $22.5 million at the end of 2024, providing a solid financial foundation to support its operations without revenue.
- Optimistic Clinical Trial Outlook: The company anticipates topline results from its phase 3 clinical trial of gedatolisib for advanced breast cancer in Q2, which, if positive, could significantly boost market confidence in its growth potential.
See More
Celcuity Reports Final 2025 Financial Results with Surprising Bottom-Line Upside
- Financial Performance Surprises: Celcuity reported a net loss of $38.4 million ($0.73 per share) for Q4 2025, which, while deeper than last year's $32.3 million, was significantly better than analysts' expectations of a $1.05 loss per share, indicating effective cost management.
- Strong Cash Position: The company's cash and cash equivalents rose to nearly $166 million at the end of Q4 2025, up from $22.5 million at the end of 2024, providing a solid financial runway for its ongoing research and development efforts, which is crucial for pre-revenue biotechs.
- Promising R&D Developments: Celcuity anticipates topline results from a phase 3 clinical trial of gedatolisib for advanced breast cancer in Q2, which, regardless of the outcome, could lay the groundwork for future revenue opportunities.
- Positive Market Reaction: Following the earnings release, Celcuity's stock surged over 4%, reflecting investor optimism about the company's future potential, particularly given its robust cash foundation.
See More
Meta Platforms Faces Legal Setbacks, Stock Drops Over 6%
- Meta Legal Setbacks: Meta Platforms' stock dropped over 6% following losses in two major legal cases concerning child safety, raising concerns about Big Tech's role in social media safety and free speech protections, despite relatively minor financial penalties.
- AppLovin's Decline: AppLovin's shares fell nearly 8% due to reports of weakening e-commerce spending trends, with insufficient new client momentum to offset churn in Q1, highlighting potential challenges in maintaining growth.
- Brown-Forman's Surge: Shares of Brown-Forman rose over 14% after Bloomberg reported that French spirits company Pernod Ricard is considering a bid, indicating strong market interest in the company's future acquisition potential.
- Pony AI's Expansion Plans: Pony AI's stock fell 13% after announcing ambitious robotaxi expansion plans alongside its first quarterly profit, but an 18% revenue drop due to project timing raises concerns about margin pressures despite doubling robotaxi revenue.
See More
Memory Stocks Plummet, Adobe Downgraded
- Memory Stock Decline: Shares of memory chipmakers fell sharply following Google's unveiling of a new AI model, with Sandisk dropping nearly 4% and Micron Technology, Western Digital, and Seagate Technology each declining about 2%, indicating significant memory demand pressures in the industry.
- Mining Stocks Drop: Shares of gold and silver miners fell alongside declining precious metal prices, with First Majestic Silver shedding about 5% and both Coeur Mining and Hecla Mining losing nearly 4%, reflecting a bearish sentiment in the precious metals market.
- Adobe Downgrade: Adobe's stock dipped 1.4% after William Blair downgraded it from outperform to market perform, highlighting uncertainty regarding its position as an AI winner or loser, which may impact investor confidence.
- Navan's Strong Guidance: Travel tech firm Navan soared 18% after guiding for strong revenue in 2027, expecting full-year revenue between $866 million and $874 million, exceeding market expectations, showcasing its robust growth potential in the industry.
See More
Celcuity Reports 2025 Financial Results and FDA Progress
- FDA Priority Review: Celcuity's NDA for Gedatolisib in HR+/HER2/PIK3CA wild-type advanced breast cancer has been accepted by the FDA with a Priority Review designation, setting a PDUFA goal date of July 17, 2026, which could pave the way for future commercialization.
- Increased Financial Loss: In Q4 2025, Celcuity reported a net loss of $51 million, or $0.97 per share, compared to a net loss of $36.7 million, or $0.85 per share in Q4 2024, reflecting the company's ongoing investment in research and development.
- Clinical Trial Advancements: The VIKTORIA-1 Phase 3 trial's PIK3CA wild-type cohort has completed enrollment, with updated efficacy and safety results published in the Journal of Clinical Oncology, while topline data from the PIK3CA-mutant cohort is expected in Q2 2026, potentially influencing future treatment protocols.
- Strong Cash Position: Celcuity ended the year with $441.5 million in cash and short-term investments, which is expected to fund operations through 2027, demonstrating financial resilience in its R&D and market launch efforts.
See More
Celcuity Reports $177 Million Net Loss for 2025 Amid Regulatory Progress
- Poor Financial Performance: Celcuity reported a net loss of $177 million for 2025, translating to a loss of $3.79 per share, indicating significant challenges in profitability despite holding $441.5 million in cash and short-term investments, which is expected to sustain operations through 2027.
- Increased R&D Expenses: Research and development expenses surged to $145 million in 2025, an increase of $40.8 million from the previous year, primarily driven by rising employee and consulting costs, which will exert ongoing pressure on the company's financial health and future investment capabilities.
- Significant Clinical Progress: In 2025, Celcuity achieved FDA acceptance of its new drug application for gedatolisib with priority review, and the VICTORIA-1 trial demonstrated unprecedented efficacy data, potentially setting new benchmarks for HR-positive HER2-negative advanced breast cancer treatment, thereby enhancing market competitiveness.
- Market Readiness Initiatives: The company has made substantial strides in preparing for the commercial launch of gedatolisib, including building a robust sales force and engaging with key healthcare decision-makers, which will help secure a favorable position in the future market, despite challenges in ensuring patient adherence to IV administration.
See More
